Views: 24 Author: Site Editor Publish Time: 2025-09-09 Origin: Site
Shandong Loncom, proudly announces the launch of three high-potential star products: Abrocitinib, Ritlecitinib Mesylate, and Iptacopan (For Research Use Only).
This strategic expansion of Loncom Pharma's portfolio underscores our commitment to advancing therapeutic solutions for critical health challenges worldwide. The newly available products cater to significant unmet medical needs:
Abrocitinib: A potent and selective JAK1 inhibitor indicated for the treatment of moderate-to-severe atopic dermatitis. Langnuo Pharma offers high-purity Abrocitinib to support global therapeutic development and manufacturing.
Ritlecitinib Mesylate: An innovative kinase inhibitor targeting key pathways involved in inflammatory and autoimmune conditions. This product represents a significant advancement in targeted therapy options.
Iptacopan (For Research Use Only): A promising complement factor B inhibitor currently generating significant interest in pre-clinical and early-stage research for various complement-mediated disorders. This product is offered exclusively for Research Use Only (RUO), not for human or therapeutic application.
